Edesa Biotech, Inc.
EDSA- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001540159
No open-market purchases or sales by Edesa Biotech, Inc. insiders were filed in the last 90 days; 33 institutions reported holding it in 13F filings for Q2 2026, worth $30.0M in total; no superinvestor holds it.
Holders of 5% or more of EDSA
Holders whose latest Schedule 13D or 13G filing reports 5% or more of Edesa Biotech, Inc., largest stake first. The change is against the holder's previous filing.
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| Nijhawan Pardeep | 13D/A | 19.99%2.04M shares | 0.00 ppfrom 19.99% | Feb 14, 20252 filings | Mar 2, 2026 | SEC |
| Velan Capital Investment Management LP | 13D/A | 9.99%834.7K shares | 0.00 ppfrom 9.99% | Feb 18, 20252 filings | Mar 2, 2026 | SEC |
| Nantahala Capital Management, LLC | 13G | 9.99%700.5K shares | New | May 15, 20251 filing | May 15, 2025 | SEC |
| Stonepine Capital Management, LLC | 13G | 9.90%693.6K shares | New | Feb 25, 20251 filing | Feb 25, 2025 | SEC |
| Point72 Asset Management, L.P. | 13G | 7.20%600.0K shares | New | Mar 3, 20261 filing | Mar 3, 2026 | SEC |
| Perceptive Advisors LLC | 13G | 6.70%563.2K shares | New | Mar 16, 20261 filing | Mar 16, 2026 | SEC |
Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.
13D and 13G filings
10 Schedule 13D and 13G filings on Edesa Biotech, Inc., newest first, including old-format filings without a stake.
| Filed (ET) | Filer | Form | Stake | Change | Event date | Filing |
|---|---|---|---|---|---|---|
| Mar 16, 20264:00 PM ET | Perceptive Advisors LLCand 2 others | 13G | 6.70%563.2K shares | New | Mar 9, 2026 | SEC |
| Mar 3, 20264:25 PM ET | Point72 Asset Management, L.P.and 2 others | 13G | 7.20%600.0K shares | New | Feb 24, 2026 | SEC |
| Mar 2, 20267:03 PM ET | Velan Capital Investment Management LPand 8 others | 13D/A | 9.99%834.7K shares | 0.00 ppfrom 9.99% | Feb 26, 2026 | SEC |
| Mar 2, 20265:11 PM ET | Nijhawan Pardeepand 4 others | 13D/A | 19.99%2.04M shares | 0.00 ppfrom 19.99% | Feb 26, 2026 | SEC |
| May 15, 20254:46 PM ET | Nantahala Capital Management, LLCand 2 others | 13G | 9.99%700.5K shares | New | Mar 31, 2025 | SEC |
| Feb 25, 20255:16 PM ET | Stonepine Capital Management, LLCand 3 others | 13G | 9.90%693.6K shares | New | Feb 13, 2025 | SEC |
| Feb 18, 20255:48 PM ET | Velan Capital Investment Management LPand 8 others | 13D | 9.99%693.6K shares | New | Feb 12, 2025 | SEC |
| Feb 18, 20254:15 PM ET | Satterfield Thomas A Jr | 13G/A | 0.00%0 shares | −6.70 ppfrom 6.70%Below 5% | Feb 13, 2025 | SEC |
| Feb 14, 20255:16 PM ET | Nijhawan Pardeepand 4 others | 13D/A | 19.99%1.60M shares | – | Feb 12, 2025 | SEC |
| Feb 12, 20258:00 AM ET | Satterfield Thomas A Jr | 13G/A | 6.70%232.2K shares | – | Dec 31, 2024 | SEC |
Form 144: proposed insider sales
Notices from officers, directors and other affiliates planning to sell Edesa Biotech, Inc. shares.
No Form 144 notices for Edesa Biotech, Inc. are on file.